A Troubling Lab Report 6-4-07 Portfolio - Stockpickr! Your Source for Stock Ideas

A Troubling Lab Report 6-4-07

4872 views

TheStreet.com Rating: B

Rate Now:

average rating: 0.00 / 0 ratings

printer friendly

send to a friend

Created by Barrons

DESCRIPTION:

Date updated:06-02-2007

FANS OF ABBOTT LABORATORIES ARE FOCUSED on the company's launch of a new drug-coated cardiac stent, which they believe could trump competitors' products and snare up to 40% of the $5 billion market. Expectations for the product have helped fuel a 50% increase in the past 18 months in shares of the Abbott Park, Ill.-based health-care concern, which closed Friday at 56.30.

But investors may be overlooking the fact that most of Abbott's profits come from its slower-growth, lower-multiple pharmaceutical division, not jazzy technologies. And some prominent doctors have started questioning the safety and efficacy of one of Abbott's best-selling drugs, TriCor, which helps patients lower triglycerides, a type of non-cholesterol fat.

GSK
Glaxosmithkline P
$41.47
-1.87%
$41.41

Concerns about fenofibrate center on creatinine, a substance produced by the muscles and eliminated by the kidneys. A rise in creatinine typically indicates some sort of kidney malfunction. Fenofibrates and other fibrate drugs have been known to result in elevated creatinine levels. A study published in March in the Journal of the American Medical Association by Dr. Steven Nissen, chairman of the department of cardiovascular medicine at the Cleveland Clinic, showed that 19 patients, or 38% in a control group that took fenofibrate, saw their creatinine levels rise above what is considered the upper limits of normal

People owning GSK also tend to own: ABT DGX EPD FMD JNJ JOSB JTX

TheStreet.com Rating: B- What is this?

MRK
Merck Co Inc
$36.21
-0.22%
$36.16

Nissen also raised concerns about Vioxx as well

People owning MRK also tend to own: C CAT DE FNM FRE GE KO

TheStreet.com Rating: B- What is this?

ABI
Safety First Trus
$11.47
0.00%
$N/A

Barrons feels that the stock is pricey at 56- especially as questions about TriCor seem destined to grow

People owning ABI also tend to own: ABT AET BAX BDX BIIB BMY CI

TheStreet.com Rating: No Rating What is this?

AMGN
Amgen Inc.
$56.35
-0.27%
$56.49

No Analysis added

People owning AMGN also tend to own: AAPL GE SGP CECE MRVL OMRI ANF

TheStreet.com Rating: B What is this?

DNA
N/a
$80.43
0.00
$80.43

No Analysis added

People owning DNA also tend to own: AAPL DSCM GOOG XOM DW ELX GLW

TheStreet.com Rating: No Rating What is this?

ABT
Abbott Laboratori
$54.49
+0.76%
$54.20

No Analysis added

People owning ABT also tend to own: AGN BMY BRL CEPH ENDP FRX HSP

TheStreet.com Rating: A- What is this?

Comments not available

Dividend Stocks for the Week

By Jonas Elmerraji Posted on Dec. 1, 2009 After an earnings season that has brought a significant stream of dividend-increasers, stocks are taking a step back, with jus...

12.01.09 | 13:52 PM

This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Dec. 1, 2009 Bullish and Bearish: Each week, Barron’s publishes bullish and bearish stories on a variety of stocks. We present summaries o...

12.01.09 | 12:23 PM

Cramer's Take on Headline Stocks...

Posted on Dec. 1, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...

12.01.09 | 11:45 AM

Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 30, 2009 With Black Friday behind us and another data-heavy week ahead, it’s time to turn once again to Rocket Stocks, our list of b...

11.30.09 | 09:16 AM

General market Technical Analysi...

11.14.07 | 22:55 PM From author ZA

The Presidential/Political Thread

01.02.08 | 08:05 AM From author Dave Cox

Nymph's Trading Daily Trading Diary

04.13.09 | 01:10 AM From author Trading Nymph

Options-Selling Short

12.01.09 | 06:48 AM From author Knocka

more forums